Alpha Cognition Drug Patent Portfolio
Alpha Cognition owns 1 orange book drug protected by 2 US patents Given below is the list of Alpha Cognition's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11795176 | Solid forms of Alpha-1062 gluconate | 13 Jan, 2042 | Active |
| US9763953 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | 01 Dec, 2026 | Active |
Alpha Cognition's Family Patents
Alpha Cognition Drug List
Given below is the complete list of Alpha Cognition's drugs and the patents protecting them.
1. Zunveyl
Zunveyl is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11795176 | Solid forms of Alpha-1062 gluconate |
13 Jan, 2042
(17 years from now)
| Active |
| US9763953 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
01 Dec, 2026
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zunveyl's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List